Analyst Sara Nik from H.C. Wainwright reiterated a Buy rating on Curis and keeping the price target at $17.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sara Nik’s rating is based on the promising early data from Curis’s ongoing Phase 1/2 study of emavusertib in combination with venetoclax and azacitidine for frontline AML treatment. The initial results indicate that emavusertib can significantly enhance the response in patients, with a notable 62.5% achieving undetectable minimal residual disease (uMRD). This suggests a synergistic effect with the existing treatment regimen.
Furthermore, the study highlights that patients reached uMRD relatively quickly, and none of the patients who remained MRD+ experienced disease progression, indicating potential disease control benefits. The safety profile of the triplet combination appears manageable, which is crucial given the toxicity challenges of the standard treatment. These factors collectively suggest that emavusertib could offer a distinct advantage over current therapies, justifying further clinical evaluation and supporting a Buy rating for Curis’s stock.